$ORXOF News
Last published 3y ago
- 3y agoORXOFORXOYOrexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdosePR NewswireOX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten fatal opioid overdoses in the US involve synthetic opioidsIf approved, the US launch is expected to be
- 3y agoORXOFORXOYOrexo Interim Report Q4 2022, incl. Full Year ReportPR NewswireUPPSALA, Sweden, Jan. 26, 2023 /PRNewswire/ -- Important steps forward in a challenging environment Q4 2022 highlights Total net revenues of SEK 156.1 m (144.0) EBITDA of SEK -53.1 m (-48.5), EBITDA
- 3y agoORXOFORXOYOrexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companiesPR NewswireOrexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX®, showing excellent protein stabilityOrexo has initiated two exploratory feasibility studies applying
- 4y agoORXOFORXOYOrexo Interim Report Q3 2022PR NewswireUPPSALA, Sweden, Nov. 3, 2022 /PRNewswire/ -- Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of SEK 161.0 m (145.9) EBITDA of SEK -32.4 m (-47.4), EBITDA excluding legal
- 4y agoORXOFORXOYOrexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUDPR NewswireStudy evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD)The study enrolled 437
- 4y agoORXOFORXOYOrexo appoints Edward Kim, M.D., as new Chief Medical OfficerPR NewswireUPPSALA, Sweden, Oct. 26, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today welcomes Edward (Ed) Kim, M.D., as new Chief Medical Officer (CMO). Ed Kim will succeed Michael Sumner, M.D., who has held
- 4y agoORXOFORXOYOrexo's Nomination Committee for the Annual General Meeting 2023PR NewswireUPPSALA, Sweden, Oct. 17, 2022 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) that will take place on April 18, 2023, a Nomination Committee has been appointed comprising the same members as ahead of the AGM
- 4y agoORXOFORXOYOrexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactionsPR NewswireAll four investigational formulations of OX640 were extensively absorbed and rapidly achieved clinically relevant plasma levels of epinephrine Data available today indicates significantly improved stability compared to
- 4y agoORXOFORXOYOrexo's partner Trinity Health today announces the availability of vorvida® and deprexis® to patientsPR NewswireUPPSALA, Sweden, Sept. 7, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics.
- 4y agoORXOFORXOYFirst patent issued in Europe for Orexo's adrenaline product OX640PR NewswireUPPSALA, Sweden, Sept. 1, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo's nasal adrenaline rescue medicat
- 4y agoORXOFORXOYOrexo Interim Report Q2 2022PR NewswireUPPSALA, Sweden, July 14, 2022 /PRNewswire/ -- Good tailwind in the financial development Q2 2022 highlights Total net revenues of SEK 147.8 m (142.8) EBITDA of SEK -32.5 m (-41.1) Net earnings of SEK -35.8 m (-73.7) US Pharma segmen
- 4y agoORXOFORXOYOrexo's digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply SchedulePR NewswireOrexo is granted a Veterans Affairs Federal Supply Schedule contract for deprexis® in the US and will be reimbursed and made available by the federal government for use within the Veterans Affairs Health System, Indian Health Service and Department of
- 4y agoORXOFORXOYOrexo's nasal adrenaline rescue medication OX640 enters clinical developmentPR NewswireOX640 has the potential to provide important benefits to patients and healthcare systems ensuring the correct adrenaline dose is both reliably and conveniently available - for the emergency treatment of allergic reactions If approved, the product will
- 4y agoORXOFORXOYOrexo Interim Report Q1 2022PR NewswireUPPSALA, Sweden, April 28, 2022 /PRNewswire/ -- Promising start to 2022 Q1 2022 highlights Total net revenues of SEK 159.4 m (132.3) EBITDA of SEK 2.8 m (-23.9) Net earnings of SEK -23.
- 4y agoORXOFORXOYOrexo's partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosisPR NewswireUPPSALA, Sweden, April 27, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248), a drug candidate for the treatment of systemic scleros
- 4y agoORXOFORXOYReport from Orexo AB's annual general meetingPR NewswireUPPSALA, Sweden, April 21, 2022 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 21 April 2022 resolved, in accordance with the nomination committee's proposal, that the number of board
- 4y agoORXOFORXOYOrexo publishes 2021 Annual ReportPR NewswireUPPSALA, Sweden, March 31, 2022 /PRNewswire/ -- Orexo's Annual Report for the 2021 has been published. The Annual Report can be downloaded on the company's website, www.orexo.com, and a PDF is attached to this press release. The Swedish version is also
- 4y agoORXOFORXOYNotice of Annual General Meeting of OrexoPR NewswireUPPSALA, Sweden, March 21, 2022 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Thursday 21 April 2022, at 16.00 pm in Orexo's facilities at
- 4y agoORXOFORXOYOrexo appoints Fredrik Järrsten as new CFOPR NewswireUPPSALA, Sweden, March 11, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company has appointed Fredrik Järrsten as new Chief Financial Officer (CFO) and a member of the management team, starting at latest in e
- 4y agoORXOFORXOYOrexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug ListPR NewswireUPPSALA, Sweden, Feb. 24, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today information about improved market access position for ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) for opioid dependence. This
- 4y agoORXOFORXOYOrexo Q4 2021, incl. Full Year ReportPR NewswireUPPSALA, Sweden, Jan. 27, 2022 /PRNewswire/ -- Ready to capitalize on a strong foundation Q4 2021 highlights Total net revenues of SEK 144.0 m (159.2) Net earnings of SEK -66.0 m (-49.6) EBITDA of SEK -48.5 m (1.0) US Pharma segment (ZUBSOL
- 4y agoORXOFORXOYOrexo develops a nasal adrenaline medication based on the novel amorphOXTM platformPR NewswireUPPSALA, Sweden, Dec. 2, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions. Ad
- 4y agoORXOFORXOYOrexo provides information about its new proprietary drug delivery platform - amorphOXTMPR Newswire- amorphOXTM is a novel and inventive drug delivery platform that can be used to develop highly differentiated products with various active ingredients and administration routes - The amorphOXTM platform provides for exce
- 4y agoORXOFORXOYOrexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124PR NewswireUPPSALA, Sweden, Nov. 16, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully completed the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124. The study met its prim
- 5y agoORXOFORXOYOrexo's Nomination Committee for the Annual General Meeting 2022PR NewswireUPPSALA, Sweden, Nov. 1, 2021 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2022, Orexo has appointed a Nomination Committee which represents approximately 38 percent of the number of votes in the company as of September 30, 2021. The No
- 5y agoORXOFORXOYMODIA™ paper published in the Journal of Medical Internet Research Mental HealthPR NewswireUPPSALA, Sweden, Oct. 18, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA™) for Adjunctive Trea
- 5y agoORXOFORXOYOrexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trialPR NewswireUPPSALA, Sweden, July 16, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124. The first cohort of hea
- 5y agoORXOFORXOYSober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with OrexoPR NewswireMORRISTOWN, N.J., July 12, 2021 /PRNewswire/ -- Sober Grid, the largest social media network for those in addiction recovery, and Orexo, a Swedish pharmaceutical company, today announced that Sober Grid's more than 300,000 users will gain access to Orexo
- 5y agoORXOFORXOYOrexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®PR NewswireUPPSALA, Sweden, July 12, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) and Sober Grid, the largest social media network for those in addiction recovery, today announced that Sober Grid's more than 300,000 users will gain access to Ore
- 5y agoORXOFORXOYOrexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUDPR NewswireUPPSALA, Sweden, July 1, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination with sublingual buprenorphine/naloxone,
- 5y agoORXOFORXOYOrexo continues to strengthen ZUBSOLV's patent portfolio with two new patentsPR NewswireUPPSALA, Sweden, June 2, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office (USPTO) has issued another two patents relating to ZUBSOLV®, Orexo's sublingual buprenorphine and naloxone t